Pricing and Reimbursement: How Price Controls Shape Quoting Strategy in Iran

1. Key takeaways

Iran applies price support and control arrangements to pharmaceuticals and certain medical products, and the pricing of medical devices is subject to price management by the competent authorities. GRZAN’s judgment is that the quoting strategy must shift from cost-plus to working backwards from the price ceiling: first establish the price level the Iranian market can accept, then reverse-engineer the cost structure and the supply model from that level. A company that builds its quotation on cost-plus logic and only afterwards encounters the price management framework is forced to redo the entire commercial plan at the pricing stage — a rework that touches manufacturing cost targets, margin expectations, partner terms and sometimes the product configuration itself. Two structural forces shape the acceptable price level. Subsidies to domestic production give locally made products a natural price advantage, so imports positioned in the low and mid price bands compete head-on with subsidised domestic products with limited odds of success. And the self-sufficiency objective in the Seventh National Development Plan reinforces that trend over time, which means the disadvantage of a price-led import strategy grows rather than shrinks. The practical conclusion is that import pricing should be carried by technical differentiation, with the price band chosen first and the cost structure derived from it.

• Iran grants subsidy support to the production of pharmaceuticals, medical devices and infant formula; exports of the related products have previously been restricted.
• Device pricing is subject to price management by the competent authorities; the specific scope and procedures of price control are a practical estimate.
• Quoting strategy must move from cost-plus to reverse engineering from the acceptable price ceiling.
• Subsidised domestic products hold a natural price advantage; imports should differentiate on technology rather than compete on price.
• VAT at the statutory standard rate of 9%, and possible adjustments through the annual budget law, are reflected in the end price; quotations must state whether they are tax-inclusive.

2. Legal basis

The pricing environment described here rests on the subsidy and price support regime, on the VAT framework that shapes end prices, and on the self-sufficiency provision of the Seventh National Development Plan. The items below state each basis and its verification status.

1. Price support and control: Iran grants subsidy support to the production of pharmaceuticals, medical devices and infant formula, and exports of the related products have previously been restricted — see public statements by the head of the Iranian Food and Drug Administration (reported by the Tehran Times, Iranian year 1400); the specific applicable scope and procedures of price control are a practical estimate.
2. VAT Law (approved 23 May 2021, effective 3 January 2022): standard rate 9%, which affects end pricing.
3. Seventh National Development Plan Law of the Islamic Republic of Iran, Chapter 14, Article 72(a): enhancing self-sufficiency in medical devices and consumables, which affects the price competition pattern between domestic and imported products.

3. Expert insights

Insight 1: subsidies and price control narrow the space for a high-price strategy. Iran subsidises the domestic production of pharmaceuticals and devices, so domestic products hold a natural advantage on price. An imported product positioned in the low and mid price bands competes head-on with subsidised domestic products, and the odds of success are limited. The imported product’s realistic competitive ground is somewhere the subsidy cannot reach — features, quality tier, configuration, or service levels that the domestic equivalent does not offer. Recognising this early changes the entire product plan, from which model variants are registered to which clinical claims are emphasised. It also changes the negotiation posture with the local agent, because the agent can only sell what the positioning supports; a product brought in as a price alternative will be pushed around on price for its whole lifecycle, while a product brought in on differentiation has a defensible reference point in every price discussion.

Insight 2: the Seventh Development Plan law reinforces this trend. Article 72(a) sets self-sufficiency in medical devices and consumables as a national objective, so domestic supply will keep increasing. The pricing strategy of imported products should therefore shift toward technical differentiation rather than price competition. Companies that plan multi-year market positions should treat the share of domestically produced alternatives as a rising variable in their pricing model, and revisit the positioning whenever a domestic equivalent for their product category appears.

Insight 3: VAT shapes the end price structure. The 9% statutory standard rate — and any adjustment made through the annual budget law — is reflected in the end price. Quotations should state clearly whether the quoted figure is tax-inclusive or tax-exclusive. Ambiguity on this point is a recurring source of margin erosion in agency arrangements, because the two parties may silently assume different tax bases when they negotiate, and the difference surfaces only at invoicing. Stating the tax basis on the quotation document itself, rather than in correspondence, removes the ambiguity at the point where it is cheapest to fix.

4. Practical recommendations

• Set the price band first, then reverse-engineer the costs: take the price level acceptable to the Iranian market as the starting point and derive the supply model from it.
• Avoid head-on price competition with subsidised domestic products: support the price with a technology-differentiated positioning.
• State the tax basis of quotations clearly: agree with the local agent on whether quotations are tax-inclusive or tax-exclusive.
• Track the applicable scope of price control: confirm whether the product to be launched falls within the price management scope.

5. Verification checklist

• □ The target price band has been determined and the cost structure reverse-engineered from it
• □ It has been confirmed whether the product to be launched falls within the price management scope
• □ The positioning has shifted to technical differentiation, avoiding head-on price competition with subsidised products
• □ Quotations clearly state the tax-inclusive or tax-exclusive basis
• □ The impact of the Seventh National Development Plan law on domestic supply is being tracked

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iranian market. Our team coordinates local import arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com